Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan
Summary Background Comparative long‐term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for prevention of disease progression to hepatocellular carcinoma (HCC) among high‐risk patients with chronic hepatitis B (CHB)‐related compensated cirrhosis is controversial. Aims To compare...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2020-12, Vol.52 (11-12), p.1695-1706 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1706 |
|---|---|
| container_issue | 11-12 |
| container_start_page | 1695 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 52 |
| creator | Hu, Tsung‐Hui Yueh‐Hsia Chiu, Sherry Tseng, Po‐Lin Chen, Chien‐Hung Lu, Sheng‐Nan Wang, Jing‐Houng Hung, Chao‐Hung Kee, Kwong‐Ming Lin, Ming‐Tsung Chang, Kuo‐Chin Lin, Meng‐Chih Chien, Rong‐Nan |
| description | Summary
Background
Comparative long‐term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for prevention of disease progression to hepatocellular carcinoma (HCC) among high‐risk patients with chronic hepatitis B (CHB)‐related compensated cirrhosis is controversial.
Aims
To compare the long‐term efficacy of ETV and TDF in HCC prevention in patients with CHB‐related cirrhosis, and to evaluate predictive risk factors for HCC development.
Methods
From January 2008 to March 2018, 894 treatment‐naïve patients with CHB‐related compensated cirrhosis on ETV or TDF were enrolled based on the longitudinal cohort study. Data were originally collected for 7.3 years of follow‐up or after the launch of TDF in 2011. Only the 5‐year cumulative incidence and risk factors of HCC were assessed.
Result
Total 678 and 216 patients received ETV and TDF, respectively. The cumulative risk of HCC at 1, 3 and 5 years of follow‐up was 1.6%, 11.3% and 18.7%, respectively, in the ETV group; and 0.9%, 6.7% and 10.7%, respectively, in the TDF group (P = 0.0305). Univariate and adjusted‐multivariable models revealed that platelet count, alpha‐fetoprotein (AFP) levels and upper gastrointestinal (UGI) varices were independent risk factors for HCC development. TDF resulted in risk of HCC development compared to ETV with adjusted hazard ratios (aHRs) of 0.66 (95% confidence interval [CI]:0.40, 1.08; P = 0.0971), 0.69 (95% CI: 0.42, 1.14; P = 0.1488) and 0.66 (95% CI: 0.38, 1.14; P = 0.1407) under stepwise selection, propensity score adjustment, and propensity score matching multivariable models, respectively.
Conclusions
For treatment‐naïve patients with CHB‐related compensated cirrhosis with 5‐year follow‐up, after variable adjustments, propensity score approaches and subgroup analyses, TDF showed a lower rate of HCC development that did not reach statistical significance, compared to the ETV. |
| doi_str_mv | 10.1111/apt.16116 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2455177717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2455177717</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-7a5841f0b35b75343ce4f6f07b0b771dc5f79e54cf4845cb5015c7037cd85c913</originalsourceid><addsrcrecordid>eNp1kc1u1DAQgC0EokvhwAsgS1zgkNaO_3aPbUUBqRIclnPkOGOtS2IH29nV3ngE3oRXQOJNeBKcpnBAwhePR5-_Gc0g9JySM1rOuR7zGZWUygdoRZkUVU2YfIhWpJabql5TdoKepHRLCJGK1I_RCWPlGydkhX5cuz38-vrtCDpiE4ZRR51LCkeXPuNg8Q5GnYOBvp_6GdHROB8GjTvYQx_GAXzGk-8g4hKB0XsXcYg4gw82zI8cQecZK2W8_vm9yIvSlUTCB5d32Oxi8M4spVx2CV8WNEKvM3R3TYFPS-xi3IVUCOfxVruD9k_RI6v7BM_u71P06frN9upddfPh7furi5vKMMFkpbRYc2pJy0SrBOPMALfSEtWSVinaGWHVBgQ3lq-5MK0gVBhFmDLdWpgNZafo1eIdY_gyQcrN4NI8Fu0hTKmpuRBUFZUq6Mt_0NswRV-6K5Qsc-c1n6nXC2ViSCmCbcboBh2PDSXNvNamrLW5W2thX9wbp3aA7i_5Z48FOF-Ag-vh-H9Tc_Fxuyh_AwJHtIU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2461404247</pqid></control><display><type>article</type><title>Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hu, Tsung‐Hui ; Yueh‐Hsia Chiu, Sherry ; Tseng, Po‐Lin ; Chen, Chien‐Hung ; Lu, Sheng‐Nan ; Wang, Jing‐Houng ; Hung, Chao‐Hung ; Kee, Kwong‐Ming ; Lin, Ming‐Tsung ; Chang, Kuo‐Chin ; Lin, Meng‐Chih ; Chien, Rong‐Nan</creator><creatorcontrib>Hu, Tsung‐Hui ; Yueh‐Hsia Chiu, Sherry ; Tseng, Po‐Lin ; Chen, Chien‐Hung ; Lu, Sheng‐Nan ; Wang, Jing‐Houng ; Hung, Chao‐Hung ; Kee, Kwong‐Ming ; Lin, Ming‐Tsung ; Chang, Kuo‐Chin ; Lin, Meng‐Chih ; Chien, Rong‐Nan</creatorcontrib><description>Summary
Background
Comparative long‐term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for prevention of disease progression to hepatocellular carcinoma (HCC) among high‐risk patients with chronic hepatitis B (CHB)‐related compensated cirrhosis is controversial.
Aims
To compare the long‐term efficacy of ETV and TDF in HCC prevention in patients with CHB‐related cirrhosis, and to evaluate predictive risk factors for HCC development.
Methods
From January 2008 to March 2018, 894 treatment‐naïve patients with CHB‐related compensated cirrhosis on ETV or TDF were enrolled based on the longitudinal cohort study. Data were originally collected for 7.3 years of follow‐up or after the launch of TDF in 2011. Only the 5‐year cumulative incidence and risk factors of HCC were assessed.
Result
Total 678 and 216 patients received ETV and TDF, respectively. The cumulative risk of HCC at 1, 3 and 5 years of follow‐up was 1.6%, 11.3% and 18.7%, respectively, in the ETV group; and 0.9%, 6.7% and 10.7%, respectively, in the TDF group (P = 0.0305). Univariate and adjusted‐multivariable models revealed that platelet count, alpha‐fetoprotein (AFP) levels and upper gastrointestinal (UGI) varices were independent risk factors for HCC development. TDF resulted in risk of HCC development compared to ETV with adjusted hazard ratios (aHRs) of 0.66 (95% confidence interval [CI]:0.40, 1.08; P = 0.0971), 0.69 (95% CI: 0.42, 1.14; P = 0.1488) and 0.66 (95% CI: 0.38, 1.14; P = 0.1407) under stepwise selection, propensity score adjustment, and propensity score matching multivariable models, respectively.
Conclusions
For treatment‐naïve patients with CHB‐related compensated cirrhosis with 5‐year follow‐up, after variable adjustments, propensity score approaches and subgroup analyses, TDF showed a lower rate of HCC development that did not reach statistical significance, compared to the ETV.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.16116</identifier><identifier>PMID: 33111400</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; alpha-Fetoproteins - metabolism ; Antiviral Agents - therapeutic use ; Carcinoma, Hepatocellular - epidemiology ; Cirrhosis ; Cohort Studies ; Female ; Guanine - analogs & derivatives ; Guanine - therapeutic use ; Hepatitis ; Hepatitis B ; Hepatitis B, Chronic - drug therapy ; Hepatocellular carcinoma ; Humans ; Interferon ; Liver cancer ; Liver cirrhosis ; Liver Cirrhosis - drug therapy ; Liver Neoplasms - epidemiology ; Longitudinal Studies ; Male ; Middle Aged ; Retrospective Studies ; Risk factors ; Taiwan ; Tenofovir ; Tenofovir - therapeutic use</subject><ispartof>Alimentary pharmacology & therapeutics, 2020-12, Vol.52 (11-12), p.1695-1706</ispartof><rights>2020 John Wiley & Sons Ltd</rights><rights>2020 John Wiley & Sons Ltd.</rights><rights>Copyright © 2020 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-7a5841f0b35b75343ce4f6f07b0b771dc5f79e54cf4845cb5015c7037cd85c913</citedby><cites>FETCH-LOGICAL-c3536-7a5841f0b35b75343ce4f6f07b0b771dc5f79e54cf4845cb5015c7037cd85c913</cites><orcidid>0000-0003-0009-0707 ; 0000-0002-4916-9814 ; 0000-0003-1646-9519 ; 0000-0002-8896-8133 ; 0000-0003-2388-0349 ; 0000-0001-8333-1494 ; 0000-0002-9172-1967 ; 0000-0001-6691-900X ; 0000-0002-7207-7088 ; 0000-0002-5493-4752 ; 0000-0001-7656-4695</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.16116$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.16116$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33111400$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hu, Tsung‐Hui</creatorcontrib><creatorcontrib>Yueh‐Hsia Chiu, Sherry</creatorcontrib><creatorcontrib>Tseng, Po‐Lin</creatorcontrib><creatorcontrib>Chen, Chien‐Hung</creatorcontrib><creatorcontrib>Lu, Sheng‐Nan</creatorcontrib><creatorcontrib>Wang, Jing‐Houng</creatorcontrib><creatorcontrib>Hung, Chao‐Hung</creatorcontrib><creatorcontrib>Kee, Kwong‐Ming</creatorcontrib><creatorcontrib>Lin, Ming‐Tsung</creatorcontrib><creatorcontrib>Chang, Kuo‐Chin</creatorcontrib><creatorcontrib>Lin, Meng‐Chih</creatorcontrib><creatorcontrib>Chien, Rong‐Nan</creatorcontrib><title>Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
Comparative long‐term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for prevention of disease progression to hepatocellular carcinoma (HCC) among high‐risk patients with chronic hepatitis B (CHB)‐related compensated cirrhosis is controversial.
Aims
To compare the long‐term efficacy of ETV and TDF in HCC prevention in patients with CHB‐related cirrhosis, and to evaluate predictive risk factors for HCC development.
Methods
From January 2008 to March 2018, 894 treatment‐naïve patients with CHB‐related compensated cirrhosis on ETV or TDF were enrolled based on the longitudinal cohort study. Data were originally collected for 7.3 years of follow‐up or after the launch of TDF in 2011. Only the 5‐year cumulative incidence and risk factors of HCC were assessed.
Result
Total 678 and 216 patients received ETV and TDF, respectively. The cumulative risk of HCC at 1, 3 and 5 years of follow‐up was 1.6%, 11.3% and 18.7%, respectively, in the ETV group; and 0.9%, 6.7% and 10.7%, respectively, in the TDF group (P = 0.0305). Univariate and adjusted‐multivariable models revealed that platelet count, alpha‐fetoprotein (AFP) levels and upper gastrointestinal (UGI) varices were independent risk factors for HCC development. TDF resulted in risk of HCC development compared to ETV with adjusted hazard ratios (aHRs) of 0.66 (95% confidence interval [CI]:0.40, 1.08; P = 0.0971), 0.69 (95% CI: 0.42, 1.14; P = 0.1488) and 0.66 (95% CI: 0.38, 1.14; P = 0.1407) under stepwise selection, propensity score adjustment, and propensity score matching multivariable models, respectively.
Conclusions
For treatment‐naïve patients with CHB‐related compensated cirrhosis with 5‐year follow‐up, after variable adjustments, propensity score approaches and subgroup analyses, TDF showed a lower rate of HCC development that did not reach statistical significance, compared to the ETV.</description><subject>Adult</subject><subject>Aged</subject><subject>alpha-Fetoproteins - metabolism</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Carcinoma, Hepatocellular - epidemiology</subject><subject>Cirrhosis</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - therapeutic use</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Interferon</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver Neoplasms - epidemiology</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Taiwan</subject><subject>Tenofovir</subject><subject>Tenofovir - therapeutic use</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAQgC0EokvhwAsgS1zgkNaO_3aPbUUBqRIclnPkOGOtS2IH29nV3ngE3oRXQOJNeBKcpnBAwhePR5-_Gc0g9JySM1rOuR7zGZWUygdoRZkUVU2YfIhWpJabql5TdoKepHRLCJGK1I_RCWPlGydkhX5cuz38-vrtCDpiE4ZRR51LCkeXPuNg8Q5GnYOBvp_6GdHROB8GjTvYQx_GAXzGk-8g4hKB0XsXcYg4gw82zI8cQecZK2W8_vm9yIvSlUTCB5d32Oxi8M4spVx2CV8WNEKvM3R3TYFPS-xi3IVUCOfxVruD9k_RI6v7BM_u71P06frN9upddfPh7furi5vKMMFkpbRYc2pJy0SrBOPMALfSEtWSVinaGWHVBgQ3lq-5MK0gVBhFmDLdWpgNZafo1eIdY_gyQcrN4NI8Fu0hTKmpuRBUFZUq6Mt_0NswRV-6K5Qsc-c1n6nXC2ViSCmCbcboBh2PDSXNvNamrLW5W2thX9wbp3aA7i_5Z48FOF-Ag-vh-H9Tc_Fxuyh_AwJHtIU</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Hu, Tsung‐Hui</creator><creator>Yueh‐Hsia Chiu, Sherry</creator><creator>Tseng, Po‐Lin</creator><creator>Chen, Chien‐Hung</creator><creator>Lu, Sheng‐Nan</creator><creator>Wang, Jing‐Houng</creator><creator>Hung, Chao‐Hung</creator><creator>Kee, Kwong‐Ming</creator><creator>Lin, Ming‐Tsung</creator><creator>Chang, Kuo‐Chin</creator><creator>Lin, Meng‐Chih</creator><creator>Chien, Rong‐Nan</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0009-0707</orcidid><orcidid>https://orcid.org/0000-0002-4916-9814</orcidid><orcidid>https://orcid.org/0000-0003-1646-9519</orcidid><orcidid>https://orcid.org/0000-0002-8896-8133</orcidid><orcidid>https://orcid.org/0000-0003-2388-0349</orcidid><orcidid>https://orcid.org/0000-0001-8333-1494</orcidid><orcidid>https://orcid.org/0000-0002-9172-1967</orcidid><orcidid>https://orcid.org/0000-0001-6691-900X</orcidid><orcidid>https://orcid.org/0000-0002-7207-7088</orcidid><orcidid>https://orcid.org/0000-0002-5493-4752</orcidid><orcidid>https://orcid.org/0000-0001-7656-4695</orcidid></search><sort><creationdate>202012</creationdate><title>Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan</title><author>Hu, Tsung‐Hui ; Yueh‐Hsia Chiu, Sherry ; Tseng, Po‐Lin ; Chen, Chien‐Hung ; Lu, Sheng‐Nan ; Wang, Jing‐Houng ; Hung, Chao‐Hung ; Kee, Kwong‐Ming ; Lin, Ming‐Tsung ; Chang, Kuo‐Chin ; Lin, Meng‐Chih ; Chien, Rong‐Nan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-7a5841f0b35b75343ce4f6f07b0b771dc5f79e54cf4845cb5015c7037cd85c913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>alpha-Fetoproteins - metabolism</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Carcinoma, Hepatocellular - epidemiology</topic><topic>Cirrhosis</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - therapeutic use</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Interferon</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver Neoplasms - epidemiology</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Taiwan</topic><topic>Tenofovir</topic><topic>Tenofovir - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Tsung‐Hui</creatorcontrib><creatorcontrib>Yueh‐Hsia Chiu, Sherry</creatorcontrib><creatorcontrib>Tseng, Po‐Lin</creatorcontrib><creatorcontrib>Chen, Chien‐Hung</creatorcontrib><creatorcontrib>Lu, Sheng‐Nan</creatorcontrib><creatorcontrib>Wang, Jing‐Houng</creatorcontrib><creatorcontrib>Hung, Chao‐Hung</creatorcontrib><creatorcontrib>Kee, Kwong‐Ming</creatorcontrib><creatorcontrib>Lin, Ming‐Tsung</creatorcontrib><creatorcontrib>Chang, Kuo‐Chin</creatorcontrib><creatorcontrib>Lin, Meng‐Chih</creatorcontrib><creatorcontrib>Chien, Rong‐Nan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Tsung‐Hui</au><au>Yueh‐Hsia Chiu, Sherry</au><au>Tseng, Po‐Lin</au><au>Chen, Chien‐Hung</au><au>Lu, Sheng‐Nan</au><au>Wang, Jing‐Houng</au><au>Hung, Chao‐Hung</au><au>Kee, Kwong‐Ming</au><au>Lin, Ming‐Tsung</au><au>Chang, Kuo‐Chin</au><au>Lin, Meng‐Chih</au><au>Chien, Rong‐Nan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2020-12</date><risdate>2020</risdate><volume>52</volume><issue>11-12</issue><spage>1695</spage><epage>1706</epage><pages>1695-1706</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
Comparative long‐term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for prevention of disease progression to hepatocellular carcinoma (HCC) among high‐risk patients with chronic hepatitis B (CHB)‐related compensated cirrhosis is controversial.
Aims
To compare the long‐term efficacy of ETV and TDF in HCC prevention in patients with CHB‐related cirrhosis, and to evaluate predictive risk factors for HCC development.
Methods
From January 2008 to March 2018, 894 treatment‐naïve patients with CHB‐related compensated cirrhosis on ETV or TDF were enrolled based on the longitudinal cohort study. Data were originally collected for 7.3 years of follow‐up or after the launch of TDF in 2011. Only the 5‐year cumulative incidence and risk factors of HCC were assessed.
Result
Total 678 and 216 patients received ETV and TDF, respectively. The cumulative risk of HCC at 1, 3 and 5 years of follow‐up was 1.6%, 11.3% and 18.7%, respectively, in the ETV group; and 0.9%, 6.7% and 10.7%, respectively, in the TDF group (P = 0.0305). Univariate and adjusted‐multivariable models revealed that platelet count, alpha‐fetoprotein (AFP) levels and upper gastrointestinal (UGI) varices were independent risk factors for HCC development. TDF resulted in risk of HCC development compared to ETV with adjusted hazard ratios (aHRs) of 0.66 (95% confidence interval [CI]:0.40, 1.08; P = 0.0971), 0.69 (95% CI: 0.42, 1.14; P = 0.1488) and 0.66 (95% CI: 0.38, 1.14; P = 0.1407) under stepwise selection, propensity score adjustment, and propensity score matching multivariable models, respectively.
Conclusions
For treatment‐naïve patients with CHB‐related compensated cirrhosis with 5‐year follow‐up, after variable adjustments, propensity score approaches and subgroup analyses, TDF showed a lower rate of HCC development that did not reach statistical significance, compared to the ETV.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33111400</pmid><doi>10.1111/apt.16116</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-0009-0707</orcidid><orcidid>https://orcid.org/0000-0002-4916-9814</orcidid><orcidid>https://orcid.org/0000-0003-1646-9519</orcidid><orcidid>https://orcid.org/0000-0002-8896-8133</orcidid><orcidid>https://orcid.org/0000-0003-2388-0349</orcidid><orcidid>https://orcid.org/0000-0001-8333-1494</orcidid><orcidid>https://orcid.org/0000-0002-9172-1967</orcidid><orcidid>https://orcid.org/0000-0001-6691-900X</orcidid><orcidid>https://orcid.org/0000-0002-7207-7088</orcidid><orcidid>https://orcid.org/0000-0002-5493-4752</orcidid><orcidid>https://orcid.org/0000-0001-7656-4695</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2020-12, Vol.52 (11-12), p.1695-1706 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2455177717 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged alpha-Fetoproteins - metabolism Antiviral Agents - therapeutic use Carcinoma, Hepatocellular - epidemiology Cirrhosis Cohort Studies Female Guanine - analogs & derivatives Guanine - therapeutic use Hepatitis Hepatitis B Hepatitis B, Chronic - drug therapy Hepatocellular carcinoma Humans Interferon Liver cancer Liver cirrhosis Liver Cirrhosis - drug therapy Liver Neoplasms - epidemiology Longitudinal Studies Male Middle Aged Retrospective Studies Risk factors Taiwan Tenofovir Tenofovir - therapeutic use |
| title | Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T18%3A27%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Five%E2%80%90year%20comparative%20risk%20of%20hepatocellular%20carcinoma%20development%20under%20entecavir%20or%20tenofovir%20treatment%E2%80%90na%C3%AFve%20patients%20with%20chronic%20hepatitis%20B%E2%80%90related%20compensated%20cirrhosis%20in%20Taiwan&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Hu,%20Tsung%E2%80%90Hui&rft.date=2020-12&rft.volume=52&rft.issue=11-12&rft.spage=1695&rft.epage=1706&rft.pages=1695-1706&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.16116&rft_dat=%3Cproquest_cross%3E2455177717%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2461404247&rft_id=info:pmid/33111400&rfr_iscdi=true |